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Polymorphisms in the elaC homolog-2 (ELAC2)/HPC2 gene have been hypothesized to alter the risk
of prostate cancer. However, the results of the related published studies remained conflicting. We
performed a meta-analysis of 18 studies evaluating the association between ELAC2 Ser217Leu and
Ala541Thr polymorphisms and prostate cancer risk. Overall, ELAC2 Leu217 allele was associated
with increased prostate cancer risk as compared with the Ser217 allele (odds ratio (OR)¼1.13, 95%
confidence interval (CI): 1.03–1.24, P¼0.019 for heterogeneity), as well as in the heterozygote
comparison (OR¼1.21, 95% CI: 1.07–1.36, P¼0.034 for heterogeneity) and the dominant genetic
model (OR¼1.20, 95% CI: 1.07–1.35, P¼0.025 for heterogeneity). Furthermore, the ELAC2 Thr541
allele was associated with increased prostate cancer risk as compared with the Ala541 allele
(OR¼1.22, 95% CI: 1.00–0.48, P¼0.131 for heterogeneity). In the stratified analyses for Ser217Leu
polymorphism, there was significantly increased prostate cancer risk in Asian and Caucasian
populations, and studies using sporadic and familial prostate cancer cases. Similar result was found
in the Asian population in the stratified analyses for Ala541Thr polymorphism. This meta-analysis
showed evidence that ELAC2 Ser217Leu and Ala541Thr polymorphisms were associated with
prostate cancer risk, and might be low-penetrance susceptibility markers of prostate cancer.
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Introduction
Prostate cancer is the most common solid tumor
diagnosed and the second leading cause of cancer-
related death among American men, with an estimated
192280 new cases and 27360 deaths in the United States
in 2008.
1 To date, the mechanisms that underlie the
occurrence and progression of prostate cancer remain
largely unknown. Risk factors such as diet, lifestyle and
hormones have long been recognized as contributing to
the risk of prostate cancer.
2–4 In addition to age and race,
family history of prostate cancer is the only other well-
established prostate cancer risk factor.
2,5–7
The elaC homolog-2/hereditary prostate cancer
(ELAC2/HPC2) gene at 17p11 is the first candidate gene
identified for human prostate cancer on the basis of
linkage analysis and positional cloning.
8 ELAC2 was
thought to serve as a metal-dependent hydrolase and to
be potentially involved in DNA inter-strand crosslink
repair and mRNA editing.
8 Moreover, the human ELAC2
protein was shown to possess 30-tRNase activity
9 and to
interact with g-tubulin,
10 a component of the mitotic
apparatus, suggesting a possible role for ELAC2 in the
regulation of cell-cycle progression.
Mutations in ELAC2 are rare. Sequence analyses of
ELAC2 identified two common missense changes, which
may function as low-penetrance modifiers of prostate
cancer risk. The first variant, Ser217Leu, is located in
hydrophilic segment of the protein sequence, and
substitution of the hydrophobic leucine residue may
alter the protein structure. A second variant, Ala541Thr,
is adjacent to a histidine motif and may impair protein
function.
8,11 Previously, Camp et al.
12 and Severi et al.
13
performed two meta-analyses of the association of these
two variants in ELAC2 and prostate cancer risk, but
presented inconsistent results. Moreover, the number of
studies focusing on these two polymorphisms in prostate
cancer susceptibility is growing in recent years, but the
results are often conflicting.
Hence, to derive a more precise estimation of the
association of the Ser217Leu and Ala541Thr variants in
ELAC2 and prostate cancer risk, we performed a meta-
analysis of all eligible case–control studies.
Methods
Publication search
PubMed was searched using the search terms ‘ELAC2’ or
‘HPC2’ ‘polymorphism’ and ‘prostate cancer’. And the
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www.nature.com/pcanlatest search update was 9 December 2009. All published
English language papers with available full text match-
ing the eligible criteria were retrieved. Additional studies
were identified by a hand search of the references of
original studies. Of the studies with overlapping data
published by the same investigators, only the most recent
or complete study was included in this meta-analysis.
Inclusion and exclusion criteria
For inclusion in the meta-analysis, the identified articles
had to provide: (1) information on the evaluation of
Ser217Leu or Ala541Thr polymorphisms in ELAC2
and prostate cancer risk, (2) information on using a
case–control design and (3) information on contain-
ing information about available genotype frequency
that can help infer the results in the papers. The
major reasons for exclusion of studies were: (1) no
control population; (2) no usable data reported and
(3) duplicates.
Data extraction
All of the data were extracted independently by two
reviewers according to the pre-specified inclusion
criteria, and reached a consensus on all the items. For
each study, the following characteristics were collected:
the first author’s last name, year of publication, country
of origin, ethnicity, numbers of genotyped cases and
controls, source of case groups (familial or sporadic
prostate cancer cases), genotyping methods and quality
control. Different ethnic descents were categorized as
Caucasian, Asian, African or Mixed, which included
more than one ethnic descent. For studies including
subjects of familial or sporadic prostate cancer cases, data
were extracted separately for each group whenever
possible.
Statistical analysis
The strength of the association between the Ser217Leu
and Ala541Thr polymorphisms and prostate risk was
measured by odds ratios (ORs) with 95% confidence
intervals (CIs). The statistical significance of the sum-
mary OR was determined with the Z-test. For Ser217Leu
polymorphism, we first explored the association between
allele Leu217 and prostate cancer risk, as well as
heterozygote comparison (SL vs SS) and homozygote
comparison (LL vs SS) and the dominant genetic model
(SL/LL vs SS). For the Ala541Thr polymorphism, we
evaluated the same effects. Stratified analyses were also
performed by ethnicities and sources of cases.
Heterogeneity assumption was checked by a w
2-based
Q-test. A P-value more than 0.05 for the Q-test indicated
lack of heterogeneity among the studies, and so the
summary OR estimate of each study was calculated by
the fixed-effects model (the Mantel–Haenszel method).
Otherwise, the random-effects model (DerSimonian and
Laird method) was used.
14,15 To explore the reasons of
heterogeneity, subgroup analyses were performed by
grouping studies that showed similar characteristics,
such as ethnicity and source of cases. Inter-study
variance (I
2) was used to quantify the degree of
heterogeneity between studies, and percentage of I
2
was used to describe the extent of explained hetero-
geneity of the characteristics. Potential publication bias
was determined using Egger’s linear regression test by
visual inspection of a funnel plot. All statistical analyses
were performed with the Stata software (version 8.2;
StataCorp LP, College Station, TX, USA), using two-sided
P-values.
Results
There were 18 studies retrieved on the basis of the
search criteria for prostate cancer susceptibility related
to ELAC2 Ser217Leu and Ala541Thr polymor-
phisms
8,11,13,16–31 The study characteristics are summar-
ized in Table 1. Rokman et al.
31 studied both ELAC2
Ser217Leu and Ala541Thr polymorphisms, but there was
no available genotype frequency of the Ser217Leu
polymorphism in the article, so this study was included
when analyzing the association between the Ala541Leu
Table 1 Main characteristics of selected studies
First author Year Country Ethnicity Case Control Genotyping method
Suarez 2001 US Caucasian 257 355 PCR–RFLP
Suzuki 2002 Japan Asian 81 106 PCR–RFLP
Stanford 2003 Mixed Mixed 551 521 PCR–RFLP
Noonan-Wheeler 2006 US Caucasian 150 170 Prosequencing
Robbins 2008 US African 243 296 Prosequencing
Shea 2002 Tobago African 119 223 PCR–RFLP
Xu 2001 US Caucasian 362 182 PCR–RFLP
Yokomizo 2004 Japan Asian 285 233 PCR–RFLP
Meitz 2002 UK Caucasian 382 435 PCR–RFLP
Vesprini 2001 Mixed Mixed 431 1505 PCR–RFLP
Wang 2001 US Caucasian 444 502 Prosequencing
Takahashi 2003 Japan Asian 98 255 PCR-SSCP
Severi 2003 Australia Caucasian 825 732 PCR–RFLP
Fujiwara 2002 Japan Asian 350 356 PCR–RFLP
Adler 2003 Canada Caucasian 199 525 PCR–RFLP
Tavigian 2001 Canada Caucasian 429 148 Taqman
Rebbeck 2000 US Caucasian 270 250 PCR–RFLP
Rokman 2001 Finland Caucasian 574 568 PCR–RFLP
Abbreviation: RFLP, restriction fragment length polymorphism.
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Prostate Cancer and Prostatic Diseasespolymorphism and prostate cancer. Therefore, there are
17 studies with 5476 cases and 6794 controls concerning
the Ser217Leu polymorphism and 14 studies with 5120
cases and 6209 controls concerning the Ala541Leu
polymorphism. For the Ser217Leu polymorphism, there
were 9 studies of Caucasian descendents, 4 studies of
Asian descendents, 2 of African descendents and 2 of
Mixed descendents. For Ala541Thr polymorphism, there
were 7 studies of Caucasian descendents, 4 studies of
Asian descendents, 1 of African descendents and 2 of
Mixed descendents.
All the studies used frequency-matched controls to the
cases by the age, sex or ethnicity. PCR–restriction
fragment length polymorphism assay was adopted in
13 of the 18 studies, and 11 studies mentioned quality
control on genotyping, such as randomly repeated assays
or validation using directed sequencing. In addition,
Rokman et al.
31 studied both sporadic and familial
prostate cancer risk, but they did not show the data on
familial prostate cancer risk, so this study was defined as
a study of sporadic prostate cancer risk only. Therefore,
12 studies investigated sporadic prostate cancer risk,
four studies
8,25,26,28 investigated familial prostate cancer
risk and two studies
22,29 investigated both sporadic and
familial prostate cancer risk. The distribution of geno-
types in the controls was consistent with the Hardy–
Weinberg equilibrium in all studies except for two
studies.
26,27
The ELAC2 Ser217Leu polymorphism
We observed a wide variation of Leu217 allele frequen-
cies across different ethnicities. The frequency of the
Leu217 allele was 1.94% among Asian controls, which
was significantly lower than that in Caucasian controls
(29.01%, Po0.001).
In the overall analysis, the ELAC2 Leu217 allele
was associated with increased prostate cancer risk as
compared with the Ser217 allele (OR¼1.13, 95% CI:
1.03–1.24, P¼0.019 for heterogeneity), as well as in
heterozygote comparison (OR¼1.21, 95% CI: 1.07–1.36,
P¼0.034 for heterogeneity) and in the dominant genetic
model (OR¼1.20, 95% CI: 1.07–1.35, P¼0.025 for
heterogeneity), but not in homozygote comparison
(OR¼1.11, 95% CI: 0.93, P¼0.284 for heterogeneity;
Table 2 and Figure 1), and the positive association
maintained in some subgroup analyses. Specifically, in
the comparison of Leu217 and Ser217, there was
significantly increased risk of prostate cancer in Cauca-
sian population (OR¼1.12, 95% CI: 1.00–1.25, P¼0.045
for heterogeneity), Asian population (OR¼2.09, 95% CI:
1.07–4.05, P¼0.134 for heterogeneity) and among studies
with sporadic prostate cancer (OR¼1.14, 95% CI: 1.01–
1.28, P¼0.007 for heterogeneity) or familial prostate
cancer (OR¼1.14, 95% CI: 1.01–1.28, P¼0.525 for
heterogeneity; Table 2 and Figure 2). The same results
were observed also in heterozygote comparison and the
dominant genetic model.
There was significant heterogeneity for the Leu217
versus Ser217 comparison (P¼0.019 for heterogeneity),
heterozygote comparison (P¼0.034 for heterogeneity)
and dominant model comparison (P¼0.025 for hetero-
geneity), but not for homozygote comparison (P¼0.284
for heterogeneity). Consequently, we assessed the source
of heterogeneity for the Leu217 versus Ser217 compa-
rison by ethnicity, source of cases and sample size
(subjects 4200 in both case and control group). As a
result, sample size (w
2¼6.22, df¼1, P¼0.013) but not
ethnicity (w
2¼6.97, df¼3, P¼0.073) or source of cases
(w
2¼0.43, df¼1, P¼0.513) was found to account for the
substantial heterogeneity. In addition, meta-regression
analysis indicated that ethnicity could explain 46.3%
of the I
2, whereas source of cases could explain 43.3%
of the I
2.
The ELAC2 Ala541Thr polymorphism
As shown in Table 3 and Figure 3, a statistically
significant difference was observed in the comparison
of the variant Thr541 allele frequency in control popula-
tions between the Asians and Caucasians (0.27 vs 3.64%;
Po0.001). Overall, the ELAC2 Thr541 allele was asso-
ciated with increased prostate cancer risk as compared
with the Ala541 allele (OR¼1.22, 95% CI: 1.00–1.48,
P¼0.131 for heterogeneity). Moreover, significantly
elevated risk was observed among the Asian populations
(OR¼4.44, 95% CI: 1.84–10.69, P¼0.941 for heteroge-
neity) in comparison of Thr541 and Ala541, as well as in
Table 2 Stratified analyses of the ELAC2 Ser217Leu polymorphism on prostate cancer risk
Variables n
a Cases/controls Leu allele vs Ser allele SL vs SS LL vs SS SL/LL vs SS
OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b
Total 17 5476/6794 1.13 (1.03–1.24)
c 0.019 1.21 (1.07–1.36)
c 0.034 1.11 (0.93–1.31) 0.284 1.20 (1.07–1.35)
c 0.025
Ethnicities
Caucasian 9 3318/3299 1.12 (1.00–1.25)
c 0.045 1.18 (1.03–1.36) 0.097 1.15 (0.90–1.46) 0.110 1.18 (1.03–1.37) 0.054
Asian 4 814/950 2.09 (1.07–4.05) 0.134 2.37 (1.26–4.44) 0.206 1.10 (0.17–7.00) 0.690 2.24 (1.17–4.28) 0.171
African 2 362/519 1.02 (0.81–1.28) 0.619 1.17 (0.87–1.58) 0.290 0.65 (0.31–1.34) 0.542 1.11 (0.84–1.46) 0.387
Mixed 2 982/2026 1.10 (0.97–1.26) 0.286 1.09 (0.92–1.29) 0.407 1.22 (0.92–1.62) 0.363 1.11 (0.95–1.31) 0.316
Sources of cases
Sporadic 13 4043/5683 1.14 (1.01–1.28)
c 0.007 1.25 (1.07–1.47)
c 0.008 1.06 (0.88–1.28) 0.345 1.23 (1.05–1.44)
c 0.005
Familial 6 1433/1589 1.14 (1.01–1.28) 0.525 1.16 (0.99–1.36) 0.708 1.26 (0.90–1.77) 0.304 1.18 (1.01–1.38) 0.727
Abbreviations: CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.
aNumber of comparisons.
bP-value of Q-test for heterogeneity test.
cA random-effects model was used when P-value for heterogeneity test was o0.05; otherwise, a fixed-effects model was used.
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Prostate Cancer and Prostatic Diseasesheterozygote comparison (OR¼4.27, 95% CI: 1.75–10.40,
P¼0.928 for heterogeneity) and the dominant genetic
model (OR¼4.42, 95% CI: 1.82–10.74, P¼0.937 for
heterogeneity), but not among other populations in any
genetic effect models. In addition, there was no sig-
nificantly increased risk of prostate cancer among studies
with sporadic prostate cancer and familial prostate
cancer.
There was no significant heterogeneity for the Thr541
versus Ala541 comparison (P¼0.131 for heterogeneity),
homozygote comparison (P¼0.920 for heterogeneity)
and the dominant model comparison (P¼0.076 for
heterogeneity), but for heterozygote comparison
(P¼0.043 for heterogeneity). Similarly, we assessed the
source of heterogeneity for the Thr541 versus Ala541
comparison by ethnicity, source of cases and sample size
(subjects 4200 in both case and control group). As a
result, ethnicity (w
2¼10.54, df¼3, P¼0.014) but
not source of cases (w
2¼1.09, df¼1, P¼0.297) or sample
size (w
2¼0.78, df¼1, P¼0.378) was found to account for
the substantial heterogeneity. In addition, meta-regres-
sion analysis indicated that ethnicity could explain 31.5%
of the I
2, whereas source of cases could explain 22.0%
of the I
2.
Sensitivity analyses
ELAC2 Ser217Leu. Sensitivity analyses indicated that
one independent study by Severi et al.
13 was the main
origin of the heterogeneity. The heterogeneity was
effectively removed after exclusion of this study
(Leu217 vs Ser217: P¼0.204 for heterogeneity).
Although two studies
26,27 did not follow the Hardy–
Weinberg equilibrium, the summary ORs were not
effectively altered with or without including these two
studies. Moreover, no other single study influenced the
summary OR qualitatively as indicated by sensitivity
analyses.
ELAC2 Ala541Thr. Similarly, sensitivity analyses in-
dicated that no other single study influenced the
summary OR qualitatively.
Publication bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias. The shape of the funnel plots
seemed asymmetrical in allele comparison for both
polymorphisms, suggesting the presence of publication
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Figure 1 Forest plot of cancer risk associated with the ELAC2 Ser217Leu polymorphism (Leu allele vs Ser allele). The squares and horizontal
lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond
represents the summary OR and 95% CI. CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.
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Prostate Cancer and Prostatic Diseasesbias (Supplementary Figure). Then, Egger’s test was
used to provide statistical evidence of funnel plot
symmetry. As expected, the results have shown an
obvious evidence of publication bias (Leu allele vs Ser
allele, t¼3.21, P¼0.006; Thr allele vs Ala allele, t¼3.06,
P¼0.011).
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Figure 2 A forest plot of cancer risk associated with the ELAC2 Ser217Leu polymorphism (Leu allele vs Ser allele) stratified by source of
cases. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of
the variance). The diamond represents the summary OR and 95% CI. CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.
Table 3 Stratified analyses of the ELAC2 Ala541Thr polymorphism on prostate cancer risk
Variables n
a Cases/controls Thr allele vs Ala allele AT vs AA TT vs AA AT/TT vs AA
OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b
Total 14 5120/6209 1.22 (1.00–1.48) 0.131 1.23 (0.97–1.55)
c 0.043 1.64 (0.59–4.57) 0.920 1.23 (0.99–1.53) 0.076
Ethnicities
Caucasian 7 3084/3333 1.19 (0.98–1.44) 0.084 1.20 (0.91–1.57) 0.063 1.67 (0.44–6.39) 0.667 1.19 (0.94–1.52) 0.139
Asian 4 805/553 4.44 (1.84–10.69) 0.941 4.27 (1.75–10.40) 0.928 2.62 (0.11–64.67) — 4.42 (1.82–10.74) 0.937
African 1 243/296 1.22 (0.17–8.69) — 1.22 (0.17–8.72) — — — 1.22 (0.17–8.72) —
Mixed 2 988/2027 0.96 (0.71–1.30) 0.859 0.98 (0.72–1.35) 0.848 1.37 (0.22–8.41) 0.763 0.95 (0.70–1.30) 0.899
Sources of cases
Sporadic 11 4134/5246 1.14 (0.93–1.38) 0.276 1.12 (0.91–1.37) 0.294 1.64 (0.51–5.31) 0.992 1.13 (0.92–1.38) 0.275
Familial 5 986/1441 1.46 (0.93–2.28) 0.210 1.51 (0.75–3.05)
c 0.035 2.31 (0.30–17.59) 0.263 1.50 (0.84–2.68) 0.094
Abbreviations: CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.
aNumber of comparisons.
bP-value of Q-test for heterogeneity test.
cA random-effects model was used when P-value for heterogeneity test was o0.05; otherwise, a fixed-effects model was used.
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The rapid growth of human genetics creates countless
opportunities for studies of disease association. Given
the number of potentially identifiable genetic markers
and the multitude of clinical outcomes to which these
may be linked, the testing and validation of statistical
hypotheses in genetic epidemiology is a task of un-
precedented scale. Meta-analysis provides a quantitative
approach for combining the results of various studies
with the same topic, and for estimating and explaining
their diversity.
32
The present meta-analysis, including 18 published
case–control studies, explored the association between
two polymorphisms in the ELAC2 gene region and
prostate cancer risk. We found that both ELAC2
Ser217Leu and Ala541Thr polymorphisms were asso-
ciated with significant increase in prostate cancer risk.
Given the potential roles of ELAC2 in DNA inter-strand
crosslink repair, mRNA editing and cell-cycle progres-
sion, the ELAC2 polymorphisms may modulate the risk
of prostate cancer. Tavtigian et al.
8 and Vesprini et al.
11
found that the Ser217Leu variant is located in the
hydrophilic segment of the ELAC2 protein sequence,
and substitution of the hydrophobic leucine residue
may alter the protein structure, and the Ala541Thr
variant is adjacent to a histidine motif and may impair
protein function. Thus, it is reasonable that the Leu217
allele and the Thr541 allele may decrease protein
expression leading to impaired ELAC2 function. In our
meta-analysis, we found that subjects carrying the
Leu217 or Thr541 allele were associated with higher risk
of prostate cancer than those with the wild-type allele,
which confirmed the hypothesis described above.
We found evidence for the association between the
Ser217Leu polymorphism and prostate cancer risk
among Caucasians (Leu217 vs Ser217) and Asians
(Leu217 vs Ser217) but not among Africans (all genetic
models). Moreover, the Ala541Thr polymorphism was
associated with increased prostate cancer risk among
Asians but not among Caucasians and Africans in all
genetic models. It may be a possible reflection of the
differences in genetic backgrounds and gene–environ-
ment interactions in the etiology. Other factors such as
time-lag bias and publication bias may also have a
role. In time-lag bias,
33 studies with ‘negative’ results
take longer time to be published, whereas enthusiastic
results are published much more quickly. In publication
bias,
34,35 small studies with ‘negative’ results are never
published, whereas equally small studies with similar
quality but ‘positive’ results would appear in the
literature. We examined these possibilities and found
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Figure 3 A forest plot of cancer risk associated with the ELAC2 Ala541Thr polymorphism (Thr allele vs Ala allele). The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The
diamond represents the summary OR and 95% CI. CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.
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Thr541 allele carriers’ studies (especially in the Asian
studies). Furthermore, there is only one published study
using African population. Therefore, the observed ethnic
differences may be due to chance as studies with small
sample size may have insufficient statistical power to
detect a slight effect. So, further investigations are
warranted to validate the ethnic difference in the effect
of these polymorphisms on prostate cancer risk espe-
cially in African population.
In this study we also found an association between the
Ser217Leu polymorphism and prostate cancer risk
among studies using sporadic or familial prostate cancer
cases, whereas no significant difference was found in the
stratified analysis for the Ala541Thr polymorphism.
Different roles of these two polymorphisms in the
formation process of sporadic and familial prostate
cancer might contribute to this discrepancy.
There are some limitations of this meta-analysis to be
acknowledged. First, only published studies were in-
cluded in the meta-analysis; therefore, publication bias
might have occurred and our results may have a
substantial risk of being affected by such bias. Second,
these results should be interpreted with caution because
the control populations were not uniform as in most
meta-analyses. Non-differential misclassification bias is
possible because the majority of the studies did not
consider that some controls might have developed
prostate cancer in subsequent years. Third, in some
sporadic studies, a small proportion of cases with family
history were included,
18,25,27 because it is not feasible to
separate the familial cases from the sporadic cases on the
basis of available information. Fourth, our result was
based on unadjusted estimates, while a more precise
analysis should be conducted adjusted by other factors
like age, sex, and smoking and drinking status. Lack of
the information for data analysis may cause serious
confounding bias. Fifth, lack of the original data of the
reviewed studies limited our further evaluation of
potential interactions such as gene–gene, gene–environ-
ment and different polymorphic loci of the same gene,
which may also modulate cancer risk. We minimized the
likelihood of bias by developing a detailed protocol
before initiating the study, by performing a meticulous
search for published studies and by using explicit
methods for study selection, data extraction and data
analysis. Therefore, our meta-analysis also had some
advantages. First, substantial number of cases and
controls were pooled from different studies, which
significantly increased the statistical power of the
analysis. Second, the studies included in our meta-
analysis were satisfactory and strictly met our inclusion
and criterion.
Conclusions
This meta-analysis showed evidence that the ELAC2
Ser217Leu and Ala541Thr polymorphisms might be
associated with prostate cancer risk, which supported
the hypothesis that these two polymorphisms may be
low-penetrance susceptibility markers of prostate cancer.
Further prospective researches with larger numbers of
worldwide participants are expected to examine associa-
tions between ELAC2 Ser217Leu and Ala541Thr poly-
morphisms, and prostate cancer risk to make a
comprehensive and true conclusion, and other possible
confounding risk factors like age, sex, life style and race
should also be controlled when important genetic risks
for prostate cancer are assessed.
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